BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T211552
CREATED:20230330T101610Z
LAST-MODIFIED:20230330T102722Z
UID:36955-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Exciting results are expected this year\, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73\, CD39 and A2AR! \nTo ensure the community can capitalize on this\, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston\, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73\, CD39\, A2A and A2B focused therapeutics. \nJoin this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage\, utilize novel technologies and approaches through translation to clinical development to improve patient selection\, and discover new ways of finding mono and combo therapy approaches to increase potency and safety. \nTop Speakers includes: \n\nAlex Gaither\, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates\nChangyun Hu\, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more\nJoanne Lager\, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure\n\n& 15+ more expert speakers! \nDownload your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5 \nInterested in speaking? Contact info@hansonwade.com \nInterested in sponsoring? Contact sponsor@hansonwade.com
URL:http://www.pharmajournalist.com/event/2nd-annual-adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T211552
CREATED:20230314T122048Z
LAST-MODIFIED:20230314T122048Z
UID:36825-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:Next Gen Inhalation Delivery Summit
DESCRIPTION:With exciting developments in pioneering inhaled drug products from Moderna\, Vertex\, ReCode Therapeutics\, and Pieris Pharmaceuticals\, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029\, achieving cell-specific delivery\, and optimized stability remain vital challenges. \nThis June\, the hotly anticipated Next Gen Inhalation Delivery Summit will debut\, where we will unite 80+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD\, asthma\, IPF\, lung cancer or infectious disease\, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery. \nBe part of the conversation in Boston this June\, where we unpick: \n\nOvercoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit\nAdvancing your inhalation formulation techniques for improved stability and longer shelf-lives\nEnsuring device-formulation compatibility with patient compliance and patient convenience\n\nWith key speakers from the likes of Janssen\, Avalyn Pharma\, and FDA\, exciting content\, and networking opportunities\, you cannot afford to miss out! \nTo know more visit: https://ter.li/hlg9tw
URL:http://www.pharmajournalist.com/event/next-gen-inhalation-delivery-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T211552
CREATED:20230503T050638Z
LAST-MODIFIED:20230503T050638Z
UID:37123-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd ILD Summit
DESCRIPTION:Returning for the 3rd year\, the ILD Summit will lean into the industry’s key challenges\, explore pipeline opportunity development\, and look towards the future for ILD therapeutic development from idiopathic pulmonary fibrosis pipelines. From illuminating predictors of progression to define and identify the progressive fibrosis phenotypes for patient stratification to evolving clinical trial design with novel secondary and exploratory endpoints beyond FVC. This is a fantastic point in 2023 for the lung fibrosis community to come together to meet at the intersection of pulmonology and rheumatology to advance therapeutic development for ILDs. \nTo know more visit: https://ter.li/wc2uto
URL:http://www.pharmajournalist.com/event/3rd-ild-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T211552
CREATED:20230320T154738Z
LAST-MODIFIED:20230320T154738Z
UID:36873-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:Temperature Control and Logistics Summit
DESCRIPTION:Advance your end-to-end logistics strategy to deliver vital therapeutics at the RIGHT TIME\, RIGHT PLACE and the RIGHT TEMPERATURE \nJoin us in Frankfurt in June 2023 in a brand-new venue at the heart of Europe\, as once again\, we return live and in-person for 3 days of interactive sessions\, collaborative roundtables as well as formal and informal networking to maximise the value of shared insights and open discussions. \nWe meet at a time of great challenge and opportunity. How can we mitigate risk and ensure quality whilst adopting the new technologies essential to future success? In what ways can we bolster the resilience of our supply chains without compromising operational agility? How can we build a supply chain and logistics network that is both effective and environmentally sustainability? \nOnly in partnering across the supply chain can we confront these challenges; and as a community that thrives on innovation and collaboration\, we’ve built a programme centred on the fundamental challenges of our time\, including how we: \n>> Drive Digital Transformation Throughout The Supply Chain To Achieve Full End-To-End Visibility\n>>Enhance Supply Chain & Logistics Network Design To Bolster Resilience\, Security & Efficiency\n>> Partner Across The Network To Meet The Demands of An Increasingly Complex Operating Environment\n>> Leverage New Packaging Innovation To Ensure Quality & Demonstrate Regulatory Compliance\n>> Build An Environmentally Sustainability Temperature Controlled Supply Chain \nTCL 2023 will provide a deep-dive into what these industry developments mean for Pharmaceutical Logistics\, Quality Assurance & Supply Chain practitioners and focus on delivering a mix of interactive sessions\, which will enable delegates to leverage the collective knowledge of their peers and brainstorm solutions to the challenges\, which the industry is facing. \nTCL doesn’t just stand for Temperature Control and Logistics\, now it also stands for Transformation\, Collaboration and Learning! >> Download the full agenda to view full speaker line-up\, discussion details\, sponsorship opportunities\, and more!
URL:http://www.pharmajournalist.com/event/temperature-control-and-logistics-summit/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="IQPC Limited":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T211552
CREATED:20230228T084503Z
LAST-MODIFIED:20230228T084623Z
UID:36697-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Patient Engagement
DESCRIPTION:As the global healthcare system accelerates its acceptance of gene therapies as one-time\, potentially curative\, treatment options for rare diseases\, the role of patient engagement in informing drug development strategy is evolving. \nAt this interface lies the 3rd Gene Therapy Patient Engagement Summit\, uniting patient advocacy and engagement experts from leading gene therapy and gene editing drug developers\, along with patient groups and patients themselves. Talks\, workshops\, and group discussions will shed a light on how to better integrate the patient voice into gene therapy programs at crucial stages of the drug development process. \nJoin us in Boston this summer to gain the actionable insights\, tools\, and strategies you need to better implement patient input into patient-centric gene therapy programs. \nTo know more visit: https://ter.li/rbofji
URL:http://www.pharmajournalist.com/event/3rd-annual-gene-therapy-patient-engagement/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230612
DTEND;VALUE=DATE:20230614
DTSTAMP:20260515T211552
CREATED:20230323T114637Z
LAST-MODIFIED:20230323T114637Z
UID:36890-1686528000-1686700799@www.pharmajournalist.com
SUMMARY:6th Annual Pre-Filled Syringes West Coast Conference
DESCRIPTION:Assessing Device Development and Regulation for Advanced Innovation\nSponsors: Datwyler\, Haselmeier\, Mitsubishi Gas Chemical\, Nemera\, ZEON \nExhibitors: Credence MedSystems\, Kymanox\, Noble\, Owen Mumford Pharmaceutical Services\, SCHERDEL Medtec \nSAE Media Group’s 7th Annual Pre-Filled Syringes West Coast Conference will be back for 2023 in San Diego to bring together the device developers\, innovative biotech\, and big pharma. \nThis year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \nWith the injectable drug delivery industry rapidly advancing year-to-year\, administration using pre-filled syringes\, auto-injectors\, and pen-injectors are increasingly common. Innovations in device technology\, such as connected devices are leading the way in device design in addition to injectable delivery devices for novel and large volume drugs. With the need for self-administration growing\, there is an enhanced demand for on-body injectors and digitalised health as well as patient centricity. We are beginning to see environmental sustainability being incorporated into aspects of device lifecycle from design to manufacturing and the use of the device. This year’s conference looks to address these hot topics through case studies and industry insights. \nAs part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring delegates key insights to enhance their drug device portfolio\, but it will also give them the opportunity to network with key industry players.  \nBenefits of Attending: \n\nEngage with industry representatives about the latest technologies and advances within the injectable device market and directions to take to advance your device portfolio\nGain insight into new technologies for wearable injectors he delivery of novel and large volume drugs\nUnderstand the latest regulatory requirements and guidance to ensure your combination products are compliant such as meeting essential performance requirements\nDelve into aspects of primary packaging such as material components to consider during device design to ensure drug stability and safety\nExplore how digital technologies such as companion apps are being incorporated into drug delivery devices to improve user-centricity\n\nWho should attend: \nDirectors\, Heads of Departments and Managers for the following areas: \n\nDevice Development\nDevice Engineering\nCombination Product Development\nDrug Delivery Devices\nPrimary Packaging Development\nDigital Health\nLarge Volume Drug Delivery\nNovel Drug Product Formulation\nRegulatory Affairs\n\nEarly Bird Rates: \n\nEB1 – 28 Feb 2023 – US$400\nEB2 -31 March 2023 – US$200\nEB3 – 28 April 2023 – US$100\n\nAdditional Contact Info: \nT: +44 (0)20 7827 \nE: Hannah.Blake@saemediagroup.com \nW: http://www.prefilled-syringes-westcoast.com/PharmaJournalist-El
URL:http://www.pharmajournalist.com/event/6th-annual-pre-filled-syringes-west-coast-conference/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260515T211552
CREATED:20230207T095425Z
LAST-MODIFIED:20230207T095425Z
UID:36545-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders Summit Europe
DESCRIPTION:Returning as the pinnacle event in the industry\, the 4th Annual Gene Therapy for Neurological Disorders Summit Europe (6-8 June 2023\, Amsterdam) enables you to bring your gene therapy to patients in Europe. This year’s content takes a greater focus on: \n\nInnovation in preclinical models and vector technology\nShowcasing novel approaches to improve delivery in a safe manner\nOptimizing administration route to reduce the patient\nUnderstanding what needs to be done to crack the European market\n\nDownload the agenda to find out more – https://ter.li/1mmd4t \nCovering both neurodevelopmental and neurodegenerative disorders\, join 80+ of your peers in Amsterdam this June. We’ll be welcoming those leading biopharma and academia\, working in preclinical\, clinical and market access to help get safer\, more efficacious gene therapies for neurological disorders to market in Europe. \nAs the gene therapy community gets a second wind and as the clinical promise in neurology begins to be realised\, now is the time to get your hands on the latest innovations in this field to bring safe\, efficacious and commercially successful products to market in Europe.  \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/azxig5
URL:http://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders-summit-europe/
LOCATION:Room Mate Aitana\, IJdok 6\, 1013 MM\, Amsterdam\, 1013 MM\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260515T211552
CREATED:20230202T110957Z
LAST-MODIFIED:20230202T110957Z
UID:36469-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotides for CNS Summit
DESCRIPTION:With approvals in siRNA technology\, more ASOs hurtling towards human trials in neurology\, and exciting headlines in Alzheimer’s and ALS\, the draw of CNS targets for oligonucleotides has never been greater. Massive investments and growing pipelines in pharma and biotech alike are working to make these life-changing therapies a reality for previously undruggable targets. \nJoin 100+ experts and dedicated scientists at the 3rd Oligonucleotides for CNS\, the definitive industry forum bringing together leaders to problem-solve\, explore invention\, and inspire the creation of next-generation oligonucleotide drugs for neurological disorders. Gather with specialists from Biogen\, Ionis\, Genentech\, Eli Lilly\, Servier\, and Stoke\, spanning disciplines of biology\, chemistry\, toxicology\, and clinical innovation. \nTackle genomic target validation\, backbone chemistry\, effective intracellular delivery\, and potency\, increased stability for reduced dosing\, novel cerebral organoids\, CNS device delivery\, and CSF oligo distribution to uncover the best approaches for each phase in your pipeline. Take away invaluable lessons that will translate directly into optimizing your oligonucleotide pipeline for the CNS. \nTo know more visit: https://ter.li/i5y7zn
URL:http://www.pharmajournalist.com/event/3rd-oligonucleotides-for-cns-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260515T211552
CREATED:20230307T092630Z
LAST-MODIFIED:20230307T092630Z
UID:36769-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:5th Age-Related Disease Therapeutics Summit
DESCRIPTION:Whether it’s in cardiovascular disease\, Alzheimer’s or osteoarthritis\, therapeutic innovations to target the mechanisms of aging are making significant headway to clinical trials. With increased investments and recognition\, along with the escalation of the burden of age-related disease\, research and development to meet this unmet medical need has never been more important. \nThe 5th Age-Related Disease Therapeutics Summit is the only industry-focused meeting dedicated to uniting 100+ biopharma drug developers\, pioneering academics\, and prominent investors striving to develop effective\, novel drugs that promote healthy aging and overcome major translational and regulatory obstacles. \nJam-packed with the most cutting-edge insights and opportunities to reunite with and hear from your peers on the next steps forward in developing the safest and most efficacious drug to promote a healthier and enhanced quality of life. \nTo know more visit: https://ter.li/sl5og6
URL:http://www.pharmajournalist.com/event/5th-age-related-disease-therapeutics-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260515T211552
CREATED:20230208T093703Z
LAST-MODIFIED:20230208T093703Z
UID:36555-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy Potency Assay Summit
DESCRIPTION:The 2nd Cell Therapy Potency Assay will gather 100+ experts working to rationally design better potency assays to smooth the path to regulatory approval and minimize hold times with scientifically rigorous and informative potency measurements. \nWhether you are submitting your first IND or gearing up towards BLA submission\, this critical meeting of minds is your premier opportunity to join the likes of bluebird bio\, Arsenal Bio\, Takeda\, Merck\, Sana Biotechnology and more\, to gain critical updates on regulatory interactions and unpick how industry peers are approaching potency assay development. \nLeave this meeting equipped with industry insights to understand what potency assays are showing\, develop practical\, compatible\, reproducible assays; and better characterize your cell therapy products for targeted\, untargeted\, allogeneic and autologous platforms in oncology and non-oncology indications. \nTo know more visit: https://ter.li/zc871s
URL:http://www.pharmajournalist.com/event/2nd-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230530
DTEND;VALUE=DATE:20230602
DTSTAMP:20260515T211552
CREATED:20230222T124243Z
LAST-MODIFIED:20230222T124243Z
UID:36641-1685404800-1685663999@www.pharmajournalist.com
SUMMARY:5th Treg Summit
DESCRIPTION:With investment into the Treg field at an all time high\, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity\, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic\, it remains vital for Treg trailblazers to come together to recognize therapy efficacy\, determine safety and translate the next-generation of therapies into the clinic. \nThe Treg Summit returns for the 5th year to unite this dedicated community of industry and academic experts\, and remains the go-to industry forum to advance both cell and non-cell based approaches to unlock the potential of Tregs to treat indications with huge unmet clinical need. \nWith 3 jam-packed days of content across CAR-\, TCR– and polyclonal Tregs as well as IL-2\, muteins and small molecules\, you won’t want to miss this unrivalled opportunity to collaborate with your peers in the Treg field to explore clinical advances\, discuss challenges and discover next-gen methods to take Treg therapies to the next level. \nWhy Attend Now? \n\nOver $2 billion has been thrown into the Treg space in the past 8 months alone\, reflecting the potential of these therapies\n2022 saw the first-ever dosing of a human with a CAR-Treg cell therapy paving the way for the rest of the engineered Treg field\nVital clinical updates determine the safety and efficacy of Treg modulating therapies\n\nSecure your place today – https://ter.li/jddnbx
URL:http://www.pharmajournalist.com/event/5th-treg-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230516
DTEND;VALUE=DATE:20230519
DTSTAMP:20260515T211552
CREATED:20230202T110613Z
LAST-MODIFIED:20230202T110719Z
UID:36466-1684195200-1684454399@www.pharmajournalist.com
SUMMARY:2nd ALS Drug Development Summit
DESCRIPTION:With 3 days of jam-packed content and 35+ world class speakers pioneering the next wave of ALS therapies\, the 2nd ALS Drug Development Summit is biopharma’s can’t-miss meeting for the acceleration of ALS drug development pipelines. \nJoin 100+ of your biopharma peers to uncover cutting-edge ALS biomarkers\, including neurofilament light chain\, to incorporate into clinical trials\, improve in vitro and in vivo ALS preclinical models to improve translation of safe and efficacious therapies and optimize clinical trial design and endpoints to maximise data collection in an evolving standard of care. \nBrowse the full Event Guide to discover:\n\n37+ expert ALS speakers across 3 jam-packed conference days\, spanning all stages of the drug development pipeline\n\n\nDoubled pre-conference workshop content\, with 4 deep-dive workshops facilitating interactive discussions on novel ALS target discovery\, preclinical strategy\, wearable technology\, and clinical trial design\n\n\nOpening conference discussion on recent and upcoming FDA approvals to learn key takeaways from interacting with regulatory bodies\n\n\nHear directly from patient advocates and individuals living with ALS to understand their perspective on ALS drug development and engagement in clinical research\n\n\nDedicated networking\, roundtable discussion and poster sessions to share your insights with other ALS leaders in the room\n\nTo know more visit: https://ter.li/21k4zy
URL:http://www.pharmajournalist.com/event/2nd-als-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230516
DTEND;VALUE=DATE:20230518
DTSTAMP:20260515T211552
CREATED:20221209T121926Z
LAST-MODIFIED:20221209T122048Z
UID:36016-1684195200-1684367999@www.pharmajournalist.com
SUMMARY:Reuters Events: Digital Health 2023
DESCRIPTION:It’s a painful moment for healthcare. We face rampant burn out\, squeezed operating margins\, unhappy patients\, massive cost pressures and more competition than ever as disruptors continue to flood the market with convenient\, accessible care options. \nIt’s high time we collaborate around Digital Health. We must listen\, take note and work to implement the changes that our care staff and consumers demand to force the disruptive change required. Fixing our broken healthcare system demands a collective effort to connect disparate data\, streamline clinical workflows\, slash costs\, and zero in on consumer orientated\, digitally enabled care delivery. \nReuters Events: Digital Health USA 2023 (May 16-17\, San Diego) hosts 300+ digital leaders over two intensive days of collaborating\, networking\, and learning opportunities tailored to digital\, strategy\, innovation\, transformation\, information\, information security\, data science backgrounds\, to help accelerate the transformation that our consumers desire and our care teams deserve. \nTo know more visit: https://bit.ly/3F7cD60
URL:http://www.pharmajournalist.com/event/reuters-events-digital-health-2023/
LOCATION:Mission Bay Resort\, 1775 E Mission Bay Dr.\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Natalie.Diaz-Martin@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260515T211552
CREATED:20230323T114213Z
LAST-MODIFIED:20230323T114213Z
UID:36887-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:5th Annual Injectable Drug Delivery Conference
DESCRIPTION:Exploring Injectable Drug Formulations and Device Development \nSponsors: Victrex \nExhibitors: PHC Group  \nAs Part of Europe’s leading Injectable conference series\, the 5th annual Injectable Drug Delivery conference will assess innovations in drug product formulation and biologics\, new technologies in device design\, along with the latest regulatory considerations for optimal drug delivery. \n \nWith increasing demand for vaccines\, insulin\, and many other modern medicines administered via the injectable route\, there is significant growth projected in the biologics market\, particularly the injectable drug delivery and prefilled syringe market which is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. It is due to this rising demand and increased growth that the industry must come together to discuss and critically evaluate the next generation of injectable drug delivery. \nAt this year’s event we will highlight the most recent innovations within the industry\, with regard to injectable device design and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. In silico modelling will be addressed as we continue to see a move towards AI utilisation\, alongside key CMC concerns and usability of injectable devices in digital health. The conference will also highlight the significance of sustainability within the industry\, whilst providing regulatory insight on the changes that have occurred and are forecast in the coming years. \nBenefits of attending: \n\nExplore the latest trends within the Injectable drug delivery field\, with new insights into in-silico modelling\nExpand on current knowledge of device design\, with special considerations for primary and secondary packaging\nExamine injectable drug formulation strategies\, including novel formulation methodologies\nLearn how to advance the injectable drug delivery landscape through a review of current regulatory compliance\nRealise how Chemical Manufacturing and Control can further expand the industry through digitalisation strategies\n\nTo know more visit: http://www.injectable-drug-delivery.com/PharmaJournalist-EI
URL:http://www.pharmajournalist.com/event/5th-annual-injectable-drug-delivery-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260515T211552
CREATED:20230323T113857Z
LAST-MODIFIED:20230323T113857Z
UID:36881-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients Conference 2023
DESCRIPTION:The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027\, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs\, along with the increase in associated toxicities\, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. \nOur 2023 conference brings insights from leading pharmaceutical companies on how to improve hazard identification\, integrate advanced containment controls and mitigate the risk of manufacturing HPAPI. Featuring leading speakers including directors\, engineers\, and experts in validation requirements this conference provides an extensive look at how you can futureproof your pharmaceutical manufacturing facilities. \nThis two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS\, Occupational Hygiene\, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event\, including key regulatory updates\, and leading case studies from leading pharmaceutical and biotechnology companies. \nBenefits of Attending the HPAPI Conference: \n\nLEARN how to ensure advanced therapeutic manufacturing is safe for workers and patients\nINCREASE the effectiveness of your engineering containment controls by improving harmony between the worker engineer and toxicologist to ensures cost-effective design choices\nUNCOVER the best practises & opportunities for pharmaceutical companies to work alongside CMOs to effectively and efficiently scale-up HPAPI manufacturing\nREVIEW case studies on the implementation of risk-based hazard identification strategies from leading pharmaceutical companies including AstraZeneca\, CSL Behring and Merck\n\nDISCOVER future trends in containment and control technologies to future-proof your HPAPI manufacturing plant to maximsie operator safety \nTo know more visit: www.highlypotentapi.com/PharmaJournalistEL
URL:http://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-conference-2023/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230509
DTEND;VALUE=DATE:20230512
DTSTAMP:20260515T211552
CREATED:20230227T131842Z
LAST-MODIFIED:20230227T131842Z
UID:36691-1683590400-1683849599@www.pharmajournalist.com
SUMMARY:4th STING & TLR Targeting Therapies Summit
DESCRIPTION:Facilitating key conversations needed to drive forward the development of safe and effective innate stimulating immunotherapies\, the 4th STING & TLR Targeting Therapies Summit will take place\, for the first time ever in person\, in Boston on May 9-11\, 2023. \nView the official program here. \nExplore innate agonists from discovery to translation with the leaders in the space and gain insight into clinical updates\, unpack what went wrong with some failures like ADU-S100 and address critical challenges including driving down toxicity\, preclinical model selection and choosing appropriate delivery mechanisms. \nHere are some exciting highlights you cannot miss including: \n\nReviewing the clinical landscape in the past year\, key updates in innate agonists that have moved through the clinic\, and identifying the root of failed trials through integral discussions led by Beacon Targeted Therapies\, Tempest Therapeutics\, and #Indaptus Therapeutics\nAssessing the best innate agonist delivery approaches\, from data on antibody-conjugated STING agonists with Takeda Oncologyand ImmuneSensor to unpacking 7&8 Biopharma’s IV delivery to extracellular vesicle approaches with Codiak Bio \nRevisiting cancer vaccines and navigating their development with post-COVID vaccine considerations; with Elicio Therapeuticsand UT Southwestern Medicine\, exploring the use of STING / TLR adjuvants to deliver on this promising therapeutic\nVenturing beyond oncology to learn from drug developers utilizing STING & TLR agonists to treat infectious diseases and adding these potent innate activators to our arsenal to be better equipped for the next pandemic\n\nView the complete agenda and speaker line-up. \nBeing the only meeting dedicated to driving forward the development of innate immune agonists\, we encourage you to take this exciting opportunity to unite and leverage the industry’s cumulative knowledge and experience to have meaningful conversations that will translate STING & TLR agonists into effective and reliable treatment options.
URL:http://www.pharmajournalist.com/event/4th-sting-tlr-targeting-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230502
DTEND;VALUE=DATE:20230505
DTSTAMP:20260515T211552
CREATED:20230111T113431Z
LAST-MODIFIED:20230111T113431Z
UID:36220-1682985600-1683244799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Europe Summit 2023
DESCRIPTION:Uniting leading CMC\, Regulatory\, QC\, Analytical and Process Development experts\, the 4th Annual Gene Analytical Development Europe Summit is the industry’s definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development. \nHear from the likes of AstraZeneca\, MHRA\, Gyroscope\, REGENXBIO\, Biogen\, Spark Therapeutics\, and more across three days and two tracks of in-depth case studies\, interactive panel discussions\, dedicated Q&A time\, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nDon’t miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle. \nTo know more visit: https://ter.li/q8u3rf
URL:http://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-europe-summit-2023/
LOCATION:The Tower Hotel\, St. Katharine's Way\, London\, E1W 1LD\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230426
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T211552
CREATED:20230126T113838Z
LAST-MODIFIED:20230310T095341Z
UID:36359-1682467200-1682639999@www.pharmajournalist.com
SUMMARY:6th Annual Pharmaceutical Microbiology USA Conference
DESCRIPTION:6th Annual Pharmaceutical Microbiology USA Conference\nApril 26 – 27\, 2023 \nBoston\, MA\, USA \nhttp://www.pharma-microbiology-usa.com/PharmaJournalistWL \nSponsored by: LONZA \nChaired by: Donald Singer\, USP General Chapter Committee Microbiology Chair\, US Pharmacopeia  \nContamination Control and Microbial Methods Explored to Assure Product Quality and Prevention \nMicrobiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals\, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches. \nEnsuring the sterility of the finished product continues to be one of the most critical aspects of drug development\, however an array of factors is also sustaining new growth and transformation in this field. The regulatory landscape is changing\, firstly with the preparation of Annex I\, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination\, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms\, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement. \nOn top of this\, the developing integration of automation and robotics into the manufacturing pipeline\, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs\, are all highlighting the necessity of the field in Pharma. \nThis industry is ever expanding\, join our leading experts at the 6th Annual Pharmaceutical Microbiology East Coast Conference in Boston\, USA to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with the  industry professionals\, discuss revisions in regulatory and guidance documents\, and gain a deeper insights. \nEvent Hashtag: #MicrobiologyUSA  \nKey Conference Highlights: \n\nReview implementation guidance and validation for efficient microbial testing programs\nUncover how to implement effective contamination control for manufacturing and the impact throughout pharmaceutical microbiology\nLearn how to control mold contamination and apply risk-based tools to tackle recovery\nDelve into the role the microbiologist plays in bioburden assessments and holistic closure integrity testing for new drug modalities\nUnderstand innovative techniques to control contamination as it relates to cell therapy products\, combination\, and traditional microbiological drug products\n\nView the full agenda: http://www.pharma-microbiology-usa.com/PharmaJournalistWL
URL:http://www.pharmajournalist.com/event/6th-annual-pharmaceutical-microbiology-usa-conference/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T211552
CREATED:20230227T130914Z
LAST-MODIFIED:20230227T130914Z
UID:36686-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:2nd ADC Analytical Development Summit 2023
DESCRIPTION:The 2nd ADC Analytical Development Summit (April 25-27\, 2023 | Boston\, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC\, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions\, to enhance understanding of your drug and to exert control over your process. \nSee the complete 2023 event guide here. \nWith many new ADCs under development\, the analytical challenges are only increasing as the existing hurdles keep changing\, with the regulatory guidance still being limited. This is a unique touch point for drug developers to discuss the core analytical challenges the industry is facing including drug linkers\, drug substances\, drug formulation\, and drug products. \nYou and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including: \n\nYuan Gao\, Head of Analytical Development\, ADC Therapeutics \nJessica Webb\, Scientist\, Analytical Sciences\, AstraZeneca\nGuifeng Jiang\, Head of Analytical Development Pharmaceutical Operation\, Bolt Biotherapeutics\nThomas Gardinier\, Head of Materials Analysis\, Elucida Oncology\nSimon Letarte\, Director\, Gilead\nAdrienne Wildt\, Senior Director of Analytical Development\, ImmunoGen\nShuwen Sun\, Principal Scientist\, Merck & Co\nVimal Patel\, Vice President\, Head of CMC & Supply Chain\, Orum Therapeutics\nJulie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nSarah Owen\, Senior Scientist Potency Assays\, Seagen\nMelvin Flores\, Director Quality Control Analytical & Microbiology\, Sutro Biopharma\nMay Zhu\, Director of Analytical Development- External Interface Management\, Takeda\n\nJoin them here. \nWith 100+ attendees\, 4+ hours of dedicated networking\, and 3 days of exciting new content\, including a pre-conference focus day on comparability studies\, this is a conversation you won’t want to miss to hopefully\, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval
URL:http://www.pharmajournalist.com/event/2nd-adc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T211552
CREATED:20230207T094958Z
LAST-MODIFIED:20230207T094958Z
UID:36542-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Gene Therapy Durability Summit
DESCRIPTION:Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit\, join us to: \n\nLeverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV\nBetter understand what can be extrapolated and how to gain confidence in the data collected\nBuild study designs with durability in mind and explore how well preclinical models have predicted clinical durability to date\n\nHear from the likes of Pfizer\, Selecta Biosciences\, Spark Therapeutics\, Rocket Pharmaceuticals\, ASC Therapeutics and more across a preconference workshop day\, expert presentations\, interactive panel discussions\, dedicated Q&A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nWhen you attend you will: \n\nUnderstand the regulatory requirements to determine robust durability\nExplore the challenges short term immunogenicity has on durability\nNavigate how to overcome long term immunogenicity concerns on durability\nOptimize vectors constructs to maximize gene therapy durability\nDiscover how to better predict the translational success of durability when progressing from preclinical to clinical trials\n\nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/oeczu3
URL:http://www.pharmajournalist.com/event/gene-therapy-durability-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T211552
CREATED:20230202T110212Z
LAST-MODIFIED:20230202T110212Z
UID:36461-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Neuroimmunology Drug Development Summit
DESCRIPTION:With increasing prioritization for neuroscience discovery\, huge biopharma is investing in expanding its departments\, focusing on glial biology\, neuroinflammatory biomarkers\, and optimizing various approaches to target the likes of LRKK2\, TREM2\, and more. Therefore\, there is a great amount of novel and promising research to be discussed in 2023. \nUniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications\, including AD\, PD\, ALS\, and MS\, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery\, preclinical\, translational\, and clinical experts from the likes of Genentech\, Muna Therapeutics\, Biogen\, Janssen\, Bristol Myers Squibb\, Sanofi\, Takeda\, and Roche. \nWith new speakers from the hottest biopharma in neuroimmunology delivering\, a comprehensive program of pioneering and cutting-edge content\, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy\, creation\, and implementation of research\, biomarker\, and clinical hypothesis testing in neuroimmunology. \nTo know more visit: https://ter.li/w642sd
URL:http://www.pharmajournalist.com/event/5th-neuroimmunology-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T211552
CREATED:20230202T105002Z
LAST-MODIFIED:20230324T110700Z
UID:36448-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Cell Engager Summit
DESCRIPTION:The 5th Annual Cell Engager Summit is back in Boston\, MA this year – the only industry-led meeting bringing together 100+ pharma and biotech leaders will assemble for a 3-day agenda including 4 unique pre-conference workshops to delve into the biggest challenges cell engager therapeutics face. Breaking into the solid tumor\, preventing CRS and maximizing the quality of insights we gain from preclinical modeling. \nFor unmissable opportunities\, including: \n\nGain first-hand knowledge of the difficulties of developing kinase inhibitors to improve selectivity\, cross the blood-brain barrier\, and combat resistance\nUtilize cutting-edge platforms and technologies to maximise target validation and precisely predict off-target impacts to save time and costs\nEstablish long-lasting relationships by speaking with top pharma and biotech firms that are working on kinase inhibitor medicines and looking for the best-in-class solutions directly\n\nJoin your colleagues from the likes of Apexigen\, Regeneron Pharmaceuticals\, Genentech\, Roche\, Amgen\, Boehringer Ingelheim and many more at the most comprehensive cell engager event\, leaving no stone unturned\, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it. \nDownload the full event guide for your sneak peek.
URL:http://www.pharmajournalist.com/event/5th-cell-engager-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T211552
CREATED:20230126T191447Z
LAST-MODIFIED:20230126T191447Z
UID:36382-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Next Generation Cardiovascular Drug Development Summit
DESCRIPTION:Welcome to the Next Generation Cardiovascular Drug Development Summit \nExecuting Cell & Gene Therapy for Cardiac Regeneration \nFollowing technology advancements and the surge of investment in developing the next generation of cardiovascular disease drugs\, the opportunity to successfully leverage our knowledge of CRISPR/Cas9\, siRNA\, autologous iPSC therapy\, capsid engineering\, and digital medicine to reduce the soaring fatality rate has never been closer. \nThe Next Generation Cardiovascular Drug Development Summit in Boston is the only industry-led summit committed to overcoming preclinical challenges to advance your ischemic heart disease\, arrhythmogenic cardiomyopathy\, strokes and hypertension pipelines. \nTo know more visit: https://ter.li/s7qk9l
URL:http://www.pharmajournalist.com/event/next-generation-cardiovascular-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230424
DTEND;VALUE=DATE:20230426
DTSTAMP:20260515T211552
CREATED:20230315T103819Z
LAST-MODIFIED:20230315T103819Z
UID:36830-1682294400-1682467199@www.pharmajournalist.com
SUMMARY:10th Annual Pre-Filled Syringes East Coast Conference
DESCRIPTION:10th Annual Pre-Filled Syringes East Coast Conference \nApril 24 – 25\, 2023 \nBoston\, USA \nDriving Innovations in Device Design\, Connectivity and Sustainability for Advanced Parenteral Combination Product \nhttps://www.pfsamericas.com/PJ-Event-listing \nThe 10th annual Pre-Filled Syringes East Coast conference will once again play host to an international audience of drug delivery\, medical device and PFS experts to discuss emerging trends and offer innovative solutions to the challenges facing the pre-filled syringes industry\, helping attendees to secure global success for their devices. \nThe past year has seen significant developments in the injectables landscape with the evolving regulatory landscape\, accelerating opportunities in digitilization and simulation to improve device design efficiency\, and increased opportunities for connectivity to improve the user experience. \nFurthermore\, with a growing need for circular economy\, this year’s conference will assess case studies of sustainable approaches for device packaging and life cycle management\, while panel discussions\, FDA and BioPhorum addresses will evaluate current and upcoming combination product guidelines and the potential for harmonization. \nAs part of SAE Media Group’s leading drug delivery portfolio of events\, this event will bring you the key insights you need to expand and enhance your injectable device portfolio and the opportunity to network with senior players throughout the industry.  \nBenefits of Attending: \n\nDiscover the latest industry developments for improved large volume and high viscous delivery via advanced autoinjector and on body delivery system design\nAssess the growing opportunities of digitalization and simulation for improved device development efficiency and potential\nEngage in an FDA regulatory roundup from the office of combination products\, insights into EPR identification from BioPhorum and a panel discussion assessing harmonization of the regulatory landscape\nDelve into emerging technologies in injectable device design and case studies on digital integration of medical devices for improved user experience\n\nBenchmark against sustainable device packaging case studies driving the combination product industry towards circular economy
URL:http://www.pharmajournalist.com/event/10th-annual-pre-filled-syringes-east-coast-conference/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230418
DTEND;VALUE=DATE:20230421
DTSTAMP:20260515T211552
CREATED:20230127T095023Z
LAST-MODIFIED:20230127T095023Z
UID:36387-1681776000-1682035199@www.pharmajournalist.com
SUMMARY:mRNA Process Development & Manufacturing Europe
DESCRIPTION:mRNA therapeutics have catapulted into the limelight amidst the COVID-19 pandemic with multiple EMA approvals to help combat the virus. \nBringing together KOLs sharing case studies with actionable insights\, the inaugural mRNA Process Development & Manufacturing Summit Europe has been established as the first forum in Europe to support your in-house process development and manufacturing strategies. \nThe 3-day agenda has been carefully co-authored along with the leaders within the industry from the likes of BioNTech\, AstraZeneca and Genentech. A snapshot of key topics include: \n\nAssessing how dsRNA formation can be limited to reduce the purification requirements of the manufacturing process with BioNTech SE\nUncovering how to maximise biocomparability when scaling up the batch manufacturing process\, including identifying the critical process steps that introduce batch-to-batch variability with Genentech & Roche\nA snapshot of robust\, high-throughput online novel assays for identifying impurities with CureVac & AstraZeneca\nUnderstanding critical quality attributes and the differences in process development considerations for mRNA therapeutics and vaccines to achieve appropriate drug substance quality with the University of Sheffield & University Hospital Zurich\nHearing how the global market could function with a standard process platform to benefit all patients with Medicines Patent Pool\n\nThis is an opportunity to join 80+ mRNA enthusiasts from mRNA manufacturing\, analytics\, process development\, CMC\, quality control\, and drug substance to get key insights on scaling up mRNA drug substances in Europe whilst navigating mRNA process development and manufacturing regulatory guidelines to create commercially successful mRNA vaccines and therapeutics. \nTo know more visit: https://ter.li/f3ec38
URL:http://www.pharmajournalist.com/event/mrna-process-development-manufacturing-europe/
LOCATION:Sheraton Offenbach Hotel\, Am Buesing Palais\, Berliner Str. 111\,\, Offenbach am Main\, 63065\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230418
DTEND;VALUE=DATE:20230421
DTSTAMP:20260515T211552
CREATED:20230119T091650Z
LAST-MODIFIED:20230119T091650Z
UID:36291-1681776000-1682035199@www.pharmajournalist.com
SUMMARY:3rd Fc Receptor Pathway Targeted Therapies 2023
DESCRIPTION:The field of FcRn receptor targeting is gaining ground-breaking speed as Argenx\, Janssen\, UCB and Immunovant compete to tackle myasthenia gravis and biopharma invest in transformative immunological therapy for autoimmune diseases as the next big drug opportunity. \nThe 3rd Fc Receptor Pathway Targeted Therapies Summit will once again feature unmissable conversations to advance targeting FcR and the subsequent generation of Fc manipulation since real-world proof and clinical value are now at the industry’s fingertips. \nJoin 100+ of your colleagues at the 3rd Fc Receptor Pathway Targeted Therapies Summit – from the fields of immunology\, antibody engineering\, pharmacology\, toxicology\, and immuno-oncology for three days of content that is unmatched in its scope\, all focused on the optimization of FcRn\, FcγR\, and novel Fc. \nPut your stake in the ground to revolutionise autoimmune illness and position yourself in front of the next wave of blockbuster drug development. \nTo know more visit: https://ter.li/y9vxt6
URL:http://www.pharmajournalist.com/event/3rd-fc-receptor-pathway-targeted-therapies-2023/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230417
DTEND;VALUE=DATE:20230420
DTSTAMP:20260515T211552
CREATED:20221215T130847Z
LAST-MODIFIED:20221215T130847Z
UID:36096-1681689600-1681948799@www.pharmajournalist.com
SUMMARY:2nd LNP Formulation & Process Development Summit
DESCRIPTION:Turbocharging Your Next Gen LNP End-To-End Development to Deliver Curative Promises to Patients \nFollowing exciting industry updates from Verve Therapeutics’ GalNAc-LNP for PCSK9 for HFpEF treatment\, to Recode’s 5th element\, the 2nd LNP Formulation & Process Development Summit is your must-attend meeting as this nanoparticle continues to dominate the biopharmaceutical industry in 2023. \nNew for 2023\, we have curated 3 streams of content for 2nd iteration of the summit: \n\nIn depth discussions divulging IP and regulatory compliance for LNP drug products\nMaximized LNP flexibility and versatility for payloads beyond mRNA vaccines with other RNA\, DNA\, gene therapy and gene editing possibilities\nLipid Chemistry & Discovery Track: Novel lipid discovery and particle engineering to customize LNP composition for next generation delivery vehicle\nFormulation & Process Development Track: Optimize your LNP development techniques for enhanced manufacturability and product quality\, and overcome stability issues of LNP-nucleic acid drug products\nLNP CMC & Manufacturing Track: Elevating your process control\, CQAs framework for CMC\, GMP compliance for seamless scale-up\n\nThis summit will offer the most comprehensive content and exclusive data\, equipping you with end-to-end LNP development journey to exploit this lucrative non-viral delivery vehicle for various payloads to your destined cells and organs. \nIn collaboration with Intellia Therapeutics\, Pfizer\, Sanofi\, ReCode Therapeutics\, Akagera Medicines\, the 2nd LNP Formulation & Process Development Summit is committed to serving you with their lessons learned to supercharge your pipeline and deliver curative promises to patients. \nJoin us to stay at the forefront of science\, network with 350+ LNP Biology\, Chemistry\, Formulation & Process Development\, Tech Ops & Manufacturing experts to gain competitive advantage to exploit LNP potentials! \nTo know more visit: https://ter.li/ol6e27
URL:http://www.pharmajournalist.com/event/2nd-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230411
DTEND;VALUE=DATE:20230414
DTSTAMP:20260515T211552
CREATED:20230216T110911Z
LAST-MODIFIED:20230216T110911Z
UID:36612-1681171200-1681430399@www.pharmajournalist.com
SUMMARY:3rd Annual Ligase Targeting Drug Development Summit
DESCRIPTION:Hijacking E3 Ligases to Mediate Degradation & Modulation of Undrugged Targets \nAs a family of over 600 known proteins\, ligases pose immense potential as viable avenues for harnessing previously undrugged targets. Key challenges remain however to rapidly discover and identify novel and underexploited ubiquitin E3s. Furthermore\, bottlenecks exist in the development of the established ligases; Cereblon and VHL. \n \nIt is now critical that we harness Cryo-EM\, X-Ray crystallography\, and other visualization tools to fully understand the structure and function of these lesser-known E3s\, accelerate ligand screening with new and improved tools\, leverage advances in DMPK knowledge to address concerns over toxicity in Cereblon\, propel VHL from ‘academic’ to clinic\, and all in\, de-risk the translation of candidate ligases to the clinic. \nThe 3rd Ligase Targeting Drug Development Summit is returning with fresh understanding and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology\, screening tools for optimal ligase\, linker\, and ligand identification\, explore tissue specificity\, uncover the key modalities where ligases can succeed\, and showcase the novel assays that are maximizing validation to ensure success in the clinic. \nThis dedicated forum will provide an unrivaled meeting point for industry leaders all under one specialized forum to strategically accelerate and de-risk the process of identifying\, validating\, and therapeutically leveraging cell and tissue-specific ubiquitin E3 ligases for degradation or modulation of targets in oncology\, immunology\, and beyond. \nTo know more: https://ter.li/gapgsb
URL:http://www.pharmajournalist.com/event/3rd-annual-ligase-targeting-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230403
DTEND;VALUE=DATE:20230406
DTSTAMP:20260515T211552
CREATED:20230125T100124Z
LAST-MODIFIED:20230125T100331Z
UID:36350-1680480000-1680739199@www.pharmajournalist.com
SUMMARY:4th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The first TCR-based therapy approval in the US and Europe at the start of last year sparked a rush of excitement\, investment and collaborations. As further developers move into the clinic and some near commercialization\, it’s time for this community to unite to address the critical bottlenecks faced in development\, from discovery to approval\, to guarantee smooth sailing through the clinic. \nThe 4th TCR-based Therapies for Solid Tumors Summit is returning to Boston as the must-attend forum for TCR experts to come together to share industry updates and next generation engineered approaches to boost therapy safety and efficacy. \nJoin leaders and newcomers including Immunocore\, Medigene\, Immatics\, Captain T Cell and Anocca as they collaborate to guarantee tumor-specificity\, prevent cross-reactivity\, boost TCR and target discovery\, enhance solid tumor durability and explore TCR modalities. \nHuge milestones were achieved for the TCR field in 2022\, however\, there’s no time to sit back and relax. Collaborate with like-minded TCR trailblazers to secure clinical validation and streamline the road from discovery to commercialization. \nTo know more visit: https://ter.li/h6mn96
URL:http://www.pharmajournalist.com/event/4th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230328
DTEND;VALUE=DATE:20230331
DTSTAMP:20260515T211552
CREATED:20230310T091100Z
LAST-MODIFIED:20230310T091100Z
UID:36791-1679961600-1680220799@www.pharmajournalist.com
SUMMARY:8th Innate Killer Summit
DESCRIPTION:Dedicated to driving cost-effective\, efficacious\, safe\, durable\, scalable\, and globally accessible allogeneic\, cell-based\, and engager therapies\, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team\, with 4 content tracks spanning preclinical development\, clinical translation\, CMC\, process development\, and clinical scale manufacturing\, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies. \nDownload your copy of the Full Event Guide here. \nJoin over 250 experts from 120+ pioneering companies to drive novel gene engineering technologies\, gain regulatory know-how\, optimize lymphodepletion and cryopreservation\, and contrast cell sources for highly efficacious\, scalable off-the-shelf therapies. \nPromising brand-new speakers from new companies\, interactive discussion\, and engaging networking opportunities\, attend to forge new collaborations and realize the clinical potential of innate immune therapies. \nRegister your place here.
URL:http://www.pharmajournalist.com/event/8th-innate-killer-summit/
LOCATION:HILTON LA JOLLA TORREY PINES\, 10950 N. Torrey Pines Road\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR